Articles tagged with Hormone Therapy
Researchers have discovered how oxytocin acts on individual brain cells to prompt specific social behaviors. Adding oxytocin to adult mice' brains allowed them to learn and perform social tasks, suggesting potential treatments for social anxiety and post-traumatic stress disorder.
The marketing, prescribing, and selling of testosterone and growth hormone as solutions for aging-associated problems is considered disease mongering. The FDA has recently acknowledged that these treatments are not indicated for age-related decline in serum testosterone, with potential risks outweighing benefits.
Acne sufferers may benefit from a new therapy that reduces breakout frequency and intensity using ultrasound, gold-covered particles, and lasers. The treatment works by deactivating sebaceous glands, reducing sebum production and preventing bacterial growth.
A Swedish population study found that hormone therapy combined with statins significantly lowered the risk of death from any cause and cardiovascular disease in postmenopausal women. The study compared over 40,000 women who took statins with those who used hormone therapy alone or had no treatment.
The European Menopause and Andropause Society's 10-point guide provides a comprehensive approach to managing menopausal health, emphasizing individual needs and personalized care. The guide covers diagnosis, screening, treatment, and follow-up, aiming to promote health over several decades.
Research by Columbia University finds that glucocorticoid treatment restores BBB function within a day of primary blast injury, potentially reducing mandatory rest periods for military personnel. The study's positive results could lead to the development of targeted therapies using steroids to restore BBB integrity after blast injury.
A new testosterone nasal gel has been shown to effectively raise men's low testosterone levels to normal, with minimal side effects. The medication was found to be most effective when administered three times a day, resulting in improved erectile function and mood.
A new study by Rady Children's Hospital-San Diego confirms the high prevalence of mental health problems among transgender youth. Treatment with puberty blockers and cross-gender hormones improves depression, anxiety, and self-cutting behaviors in most patients.
A new review of medical literature found no link between menopausal hormone therapy and increased mortality risk. The study included 43 studies with moderate to high-quality evidence and covered over three decades.
A new study shows that letrozole at a low dose can normalize testosterone levels and sperm production in obese men with infertility. The treatment led to successful pregnancies and births in three couples, offering a promising new hope for male infertility treatments.
A study published in LGBT Health found that transgender veterans are at higher risk of developing breast cancer, with ten new cases identified. The study also highlights the importance of sensitively discussing screening methods with transgender individuals, regardless of hormone use.
A synthetic oxytocin nasal formulation reduced caloric intake in healthy men, lowering consumption of calories and fatty foods. Oxytocin also improved metabolic measures, such as insulin sensitivity.
A meta-analysis of 29 studies involving over 120,000 men found no connection between testosterone therapy and increased risk of heart problems. An observational study from Wisconsin also showed low cardiovascular event rates in both treated and untreated groups.
A new study found that 20% of men with normal testosterone levels received a prescription for testosterone therapy. The study also found that nearly half of new testosterone users did not receive prostate cancer screening during treatment.
A large study of 2,000 Australian women aged 40-65 found that 42% of those between 60-65 years old experienced hot flashes, while 62% continued to experience sexual symptoms. The study highlights the need for better treatment options for these women, many of whom are not receiving adequate care.
A new study published in Molecular Cancer Therapeutics shows that a low percentage of androgen-receptor-positive cells in triple-negative breast cancer cells can benefit from anti-androgen therapies. This finding may lead to a larger pool of patients eligible for targeted cancer therapy.
A comprehensive review of hormone therapy in transgender adults has found no significant increase in cancer risk despite previous concerns. The study, published in the Journal of Clinical and Translational Endocrinology, provides reassurance for individuals requiring hormone treatments, reducing anxiety and increasing access to care.
A recent study published in the Journal of Clinical Oncology found that household net worth, rather than just income, plays a significant role in determining breast cancer patients' ability to afford treatment. The study suggests that physicians and health insurers need to consider this economic variable to ensure equitable care.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
A survey shows that postmenopausal women with VVA report improved satisfaction with VagiCap, a vaginal estrogen treatment. The study found that 63% of women on TX-004HR VagiCap reported an improved quality of life after just two weeks of therapy.
A recent study analyzed two large surveys to gauge the use of approved and unapproved hormone therapy among US women at menopause. Women taking compounded hormones often lack understanding about the risks associated with these treatments, which are not tested in clinical trials before dispensing.
Dr. David Lim's research advances the science of parenteral nutrition associated liver disease (PNALD) in infants, finding that GLP-2 therapy improves bile flow and serum markers of cholestasis. The study also reveals alterations in FXR signaling and key bile acid transporters with GLP-2 treatment.
A large study found that hot flashes and night sweats lasted for more than 7 years in half of all midlife women, with African American women reporting the longest total VMS duration. Women with lower educational attainment, greater stress, and higher depressive symptoms experienced longer symptom durations.
A meta-analysis of 52 studies found that short-term hormone replacement therapy (HRT) use is associated with a significantly increased risk of developing the two most common types of ovarian cancer. Women who used HRT for 5 years or more had a 40% higher likelihood of developing ovarian cancer compared to those who never took HRT.
A pilot study found that non-invasive neurotechnology HIRREM significantly reduced hot flash severity scores, insomnia symptoms, and depression in premenopausal and postmenopausal women. The study suggests that HIRREM may be a safe and effective treatment option for managing menopause-related symptoms.
Researchers fuse human hormones with cow antibodies to create long-lasting treatment options for hormone deficiencies and other diseases. The new therapy shows promise in reducing the frequency of injections needed for conditions like Turner syndrome and low birth weight.
David Lim's research on parenteral nutrition associated liver disease (PNALD) in infants has provided insight into the effects of glucagon-like peptide-2 (GLP-2) therapy, improving bile flow and serum markers of cholestasis. The study suggests that GLP-2 treatment alters bile acid metabolic pathways, which are beneficial in PNALD.
A new study published in The Lancet Oncology found that older women with early-stage hormone-receptor positive breast cancers who receive hormone treatment and surgery can safely omit radiotherapy. This group of patients is at low risk of cancer recurrence, making radiotherapy unnecessary.
A comprehensive review of literature reveals a strong relationship between higher testosterone levels and reduced cardiovascular disease and risk factors. Despite four flawed studies sparking concerns, dozens of studies demonstrate benefits of testosterone therapy in reducing mortality, improving cardiovascular health, and alleviating ...
Researchers at Oregon State University have identified sulforaphane's ability to selectively kill cancer cells and alter gene expression in metasticized prostate cancer. The compound may work alongside existing approaches to treat advanced prostate cancer, with potential for therapeutic value.
A new study found that adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate cancer, reducing cancer deaths by nearly 50 percent. The treatment was also associated with fewer deaths from any cause.
A new review suggests that hormone replacement therapy (HRT) is the most effective treatment for menopausal symptoms in younger women, particularly those experiencing hot flushes and night sweats. The review highlights that HRT provides low doses of estrogen with or without progestogen to alleviate symptoms and minimize risks.
The EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program found significant improvements in survival for men with breast cancer, but not as high as for women. The study revealed distinct biological characteristics of male breast cancer, including lower rates of hormonal therapy and breast-conserving surgery.
A new NYIT study reveals that rats treated with thyroid hormones had a reduced risk of developing dangerous heart arrhythmias following a heart attack. The findings could have important implications for future treatment of human patients with heart failure, who often suffer from atrial fibrillation.
Researchers found that HSP90 inhibition increases the ability of anti-estrogen agents to block cell cycle progression, thereby thwarting replication of tumor cells. The study provides a strong rationale for combining HSP90 inhibitors with hormonal therapy in ER+ breast cancer treatment.
Researchers have successfully designed a substance combining three metabolically active hormone components (GLP-1, GIP, and glucagon) to fight metabolic diseases. The triple hormone reduces body weight by around 30 percent while improving insulin sensitivity, essentially curing obesity and diabetes in animal models.
A new study published in European Urology has found that androgen deprivation therapy (ADT) is associated with decreased survival in men with localized prostate cancer, particularly those with longer life expectancies. The research highlights the need to reconsider the use of ADT as a primary treatment for low-risk or localized cancers.
A new study published in The Journal of Urology analyzed data from three independent registries and found no increase in prostate cancer incidence among men treated with long-term testosterone therapy. The study followed over 1,000 men for up to 17 years, with a median follow-up of approximately 5 years.
A University of Cincinnati doctoral student presents research on the legal issues posed by transgendered inmates, including Eighth Amendment protections and varying policies. The study aims to create a manual for prison institutions to guide treatment of this population.
A new study of 5,695 men with low testosterone levels found that testosterone supplementation reduces the risk of major adverse cardiac events such as heart attacks and strokes. Men who received testosterone supplementation had lower rates of death and heart attacks compared to those with persistently low testosterone levels.
Researchers at the University of Michigan discovered a new hormone called NRG4 that serves as a messenger from fat cells to the liver, regulating sugar conversion into fat. Mice with elevated NRG4 levels were protected from metabolic disorders, suggesting its potential as a treatment for obesity and related diseases.
Acromegaly is usually caused by a non-cancerous tumor in the pituitary gland, leading to excessive growth hormone production and various health complications. The Endocrine Society recommends surgery as the primary therapy for most patients, offering an opportunity to examine the tumor sample and immediately lower growth hormone levels.
Researchers at Tel Aviv University have discovered a connection between innate immune system genes and ovarian longevity, which could lead to new treatments for fertility issues. Neutralizing the effects of a key protein may slow down egg destruction and improve IVF success rates.
Researchers found that generic aromatase inhibitors increased treatment adherence by 50% compared to brand-name counterparts, while also decreasing co-payment costs. The study highlights the critical need to address medication non-adherence, particularly in the context of costly oral cancer therapies.
A comprehensive meta-analysis of robust studies shows that anti-inflammatory medicines, such as aspirin, can add to the effective treatment of schizophrenia. The study suggests that selecting specific anti-inflammatory agents could lead to improved patient responses and new treatment approaches.
A federal prescription-subsidy program improved adherence to hormone therapy among low-income women with breast cancer. The program's success was attributed to lower out-of-pocket costs, which reduced disparities in adherence rates across racial and ethnic groups.
Researchers have discovered a new class of lipids in humans called fatty acid hydroxy fatty acids (FAHFAs) that are linked to reduced inflammation and improved blood sugar levels in diabetes. FAHFA levels are low in humans with a high risk for diabetes, suggesting potential therapeutic opportunities for metabolic disorders.
A new study published in Endocrinology found that testosterone treatment increased the incidence of prostate carcinomas in rats. The research suggests that testosterone alone is a weak carcinogen in male rats and creates a hospitable environment for tumors to develop when combined with cancer-causing chemicals.
The Endocrine Society advises against testosterone therapy in healthy women, citing unknown long-term risks and limited benefits. Testosterone therapy may improve sexual function in women with Hypoactive Sexual Desire Disorder, but more research is needed to determine its safety and effectiveness.
A five-year, $20 million project will evaluate the effectiveness of different treatment strategies for women with uterine fibroids by building a national database. The study aims to answer questions about treatment outcomes, fertility, and symptom recurrence.
The new guidelines emphasize the effectiveness of levothyroxine in most patients with hypothyroidism, but note that some individuals may not regain optimal health. Alternative treatments are also discussed, but no consistently strong evidence supports their superiority.
A study published in CMAJ found that metformin increases the risk of low thyroid-stimulating hormone levels in patients with hypothyroidism. Metformin monotherapy was associated with a 55% increased risk of low TSH levels compared to sulfonylurea therapy.
Research finds HE4 hormone plays key role in modulating ovarian cancer response to hormones and therapies. The study identified a mechanism by which hormonal therapies like Tamoxifen and Fulvestrant restore sensitivity to chemotherapy in HE4-overexpressing tumors.
The North American Menopause Society (NAMS) has published its first comprehensive set of evidence-based recommendations for the care of midlife women. The guide covers over 50 key topics, including vasomotor symptoms and osteoporosis, providing practical advice for clinicians and patients.
A systematic review and meta-analysis found that combining basal insulin with a GLP-1 agonist resulted in improved blood sugar control, similar rates of hypoglycaemia, and greater weight loss compared to other anti-diabetic treatments. This combination therapy showed a 92% greater likelihood of achieving target blood sugar control.
Hot flashes are a prevalent side effect of hormone decline, causing fatigue, sleep disturbance, depression, anxiety, and impaired memory. The study estimates that $339M in healthcare costs and $27M in lost wages can be prevented with effective treatment.
Researchers found that administering EPO immediately after birth significantly reduces brain damage in premature babies. This study builds on previous research showing EPO's neuroprotective effects and holds promise for preventing long-term consequences of preterm birth.
A study published in Scientific Reports found that methadone treatment significantly suppresses testosterone levels in men with opioid addiction, leading to poor quality of life and erectile dysfunction. In contrast, women using methadone for addiction treatment showed no significant change in testosterone levels.
Women seek anti-aging clinicians to treat menopausal symptoms, valuing personalized attention and perceived safety of bioidentical hormones. The study found that these women prioritize relieving symptoms, feeling energized, and avoiding chronic illnesses associated with aging.
Researchers found that bioidentical hormone treatments reduced tumor recurrence and improved cardiovascular and bone health, while also increasing physical activity and cognition. The study's results are promising but require further validation, providing a new direction in the search for alternative hormone therapies.